CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 278 enrolled
Drug / intervention
avacincaptad pegoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05536297
NCT05536297Phase 3Completed
CompareCT.gov

An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2)

Astellas Pharma Global Development, Inc.·interventional·Posted Sep 10, 2022·Updated May 18, 2026

In Brief

A Phase 3 clinical trial evaluating avacincaptad pegol for Geographic Atrophy and Age-Related Macular Degeneration. Completed, enrolled 278 participants across 117 sites in 17 countries.

Detailed Summary

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy, Age-Related Macular Degeneration
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, France, Germany, Hungary, Israel, Italy, Latvia, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedSep 10, 2022
Enrollment StartSep 26, 2022
Primary CompletionApr 10, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 3.8 years ago

Interventions

avacincaptad pegoldrug

Intravitreal Injection